Table 3.
Xpert MTB/RIF for detection of rifampicin resistance, investigations of heterogeneity
| Type of analysis (Number of studies; participants) | Median pooled sensitivity (95% CrI) | Median pooled specificity (95% CrI) | Median predicted sensitivity (95% CrI) | Median predicted specificity (95% CrI) |
| Xpert MTB/RIF accuracy for rifampicin resistance detection by MDR‐TB burden | ||||
| High MDR‐TB burden = Yes (24; 5553) | 95% (93 to 97) | 98% (96 to 99) | 95% (85 to 99) | 98% (85 to 100) |
| High MDR‐TB burden = No (25; 2467) | 97% (93 to 99) | 99% (98 to 99) | 97% (76 to 100) | 99% (95 to 100) |
| Xpert MTB/RIF accuracy for rifampicin resistance detection by history of previous tuberculosis treatment | ||||
| Previously‐treated tuberculosisa = Yes (7; 1062) | 98% (94 to 99) | 97% (93 to 99) | 98% (87 to 100) | 97% (81 to 100) |
| Previously‐treated tuberculosis = No (41, 6958) | 95% (93 to 97) | 99% (98 to 99) | 95% (86 to 99) | 98% (91 to 100) |
| Xpert MTB/RIF accuracy for detection of rifampicin resistance by median tuberculosis prevalence | ||||
| Prevalence > 11% (24; 5505) | 96% (94 to 97) | 97% (96 to 98) | 96% (87 to 99) | 97% (88 to 99) |
| Prevalence ≤ 11% (24; 2515) | 94% (89 to 97) | 99% (99 to 100) | 94% (80 to 99) | 99% (96 to 100) |
Abbreviations: CrI: credible interval; MDR‐TB: multidrug‐resistant tuberculosis. aStudies with high percentages of participants previously treated for tuberculosis.